Hanx Biopharmaceuticals buys back 32,700 H shares for HKD 0.97 million; treasury stock rises to 446,100 shares

Bulletin Express04-29 21:03

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase.

The company bought back 32,700 H shares on 29 April 2026 at prices ranging between HKD 29.06 and HKD 31.00 per share, representing a volume-weighted average repurchase price of HKD 29.74. The aggregate consideration was approximately HKD 0.97 million.

Following the transaction, issued shares (excluding treasury shares) declined by 0.024 % from 135.81 million to 135.77 million. Treasury shares increased from 413,400 to 446,100, while total issued shares remained unchanged at 136.22 million.

The repurchase forms part of the mandate approved on 12 February 2026, which authorises Hanx Biopharmaceuticals to buy back up to 13.62 million shares. To date, 446,100 shares have been repurchased under this mandate, equivalent to 0.33 % of the issued share capital on the mandate date.

In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 29 May 2026. Directors confirmed that all repurchase procedures complied with the Main Board Listing Rules and relevant legal requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136940263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136940263","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals buys back 32,700 H shares for HKD 0.97 million; treasury stock rises to 446,100 shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase.</p>\n<p>The company bought back 32,700 H shares on 29 April 2026 at prices ranging between HKD 29.06 and HKD 31.00 per share, representing a volume-weighted average repurchase price of HKD 29.74. The aggregate consideration was approximately HKD 0.97 million.</p>\n<p>Following the transaction, issued shares (excluding treasury shares) declined by 0.024 % from 135.81 million to 135.77 million. Treasury shares increased from 413,400 to 446,100, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, which authorises Hanx Biopharmaceuticals to buy back up to 13.62 million shares. To date, 446,100 shares have been repurchased under this mandate, equivalent to 0.33 % of the issued share capital on the mandate date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 29 May 2026. Directors confirmed that all repurchase procedures complied with the Main Board Listing Rules and relevant legal requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals buys back 32,700 H shares for HKD 0.97 million; treasury stock rises to 446,100 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals buys back 32,700 H shares for HKD 0.97 million; treasury stock rises to 446,100 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-29 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase.</p>\n<p>The company bought back 32,700 H shares on 29 April 2026 at prices ranging between HKD 29.06 and HKD 31.00 per share, representing a volume-weighted average repurchase price of HKD 29.74. The aggregate consideration was approximately HKD 0.97 million.</p>\n<p>Following the transaction, issued shares (excluding treasury shares) declined by 0.024 % from 135.81 million to 135.77 million. Treasury shares increased from 413,400 to 446,100, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The repurchase forms part of the mandate approved on 12 February 2026, which authorises Hanx Biopharmaceuticals to buy back up to 13.62 million shares. To date, 446,100 shares have been repurchased under this mandate, equivalent to 0.33 % of the issued share capital on the mandate date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 29 May 2026. Directors confirmed that all repurchase procedures complied with the Main Board Listing Rules and relevant legal requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1136940263","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136940263","pubTimestamp":1777467788,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase. The company bought back 32,700 H shares on 29...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药以97万港元回购3.27万股H股；库存股增至446,100股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced a next-day disclosure return dated 29 April 2026 detailing a further on-market share repurchase.\nThe company bought back 32,700 H shares on 29 April 2026 at prices ranging between HKD 29.06 and HKD 31.00 per share, representing a volume-weighted average repurchase price of HKD 29.74. The aggregate consideration was approximately HKD 0.97 million.\nFollowing the transaction, issued shares (excluding treasury shares) declined by 0.024 % from 135.81 million to 135.77 million. Treasury shares increased from 413,400 to 446,100, while total issued shares remained unchanged at 136.22 million.\nThe repurchase forms part of the mandate approved on 12 February 2026, which authorises Hanx Biopharmaceuticals to buy back up to 13.62 million shares. To date, 446,100 shares have been repurchased under this mandate, equivalent to 0.33 % of the issued share capital on the mandate date.\nIn line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 29 May 2026. Directors confirmed that all repurchase procedures complied with the Main Board Listing Rules and relevant legal requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136940263","isCrawlerRequest":true}